-
Gallein: G Protein βγ Subunit Inhibitor for Translational Wo
2026-07-01
Gallein enables precise, reproducible control of G protein βγ signaling, empowering researchers to dissect GPCR-driven pathways in cancer, immunity, and metabolic disease. This guide outlines advanced workflows, troubleshooting strategies, and key insights for maximizing experimental clarity with APExBIO's trusted inhibitor.
-
BRCA2 Prevents PARPi-Mediated PARP1 Retention to Protect HR
2026-06-30
This study uncovers a direct mechanistic link between BRCA2 and resistance to PARP inhibitors, showing how BRCA2 safeguards RAD51 filaments from destabilization caused by PARP1 retention upon PARP inhibition. These insights advance our understanding of homologous recombination deficient cancer treatment and inform the design of selective PARP inhibitor experiments.
-
RNA Pol II Inhibition Triggers Apoptosis via Pol IIA Loss
2026-06-30
Harper et al. (2025) reveal that inhibition of RNA polymerase II activates a regulated, mitochondria-mediated apoptotic pathway independent of transcriptional loss. This mechanistic insight redefines our understanding of cytotoxicity in DNA damage response and cancer biology research, highlighting a new route by which transcription-targeting therapies induce cell death.
-
SmD2 Acetylation Modulates Splicing and PARP Inhibitor Sensi
2026-06-29
This study uncovers how acetylation-dependent regulation of the core spliceosome component SmD2 influences alternative splicing, DNA repair, and sensitivity to PARP inhibition in hepatocellular carcinoma (HCC). The findings offer new insight into combinatorial strategies for targeting DNA damage repair in HCC, broadening the landscape of synthetic lethality approaches beyond BRCA-mutant tumors.
-
HyperScript™ Reverse Transcriptase: Advancing cDNA Synthesis
2026-06-29
HyperScript™ Reverse Transcriptase from APExBIO overcomes the toughest barriers in cDNA synthesis, excelling with complex and low-abundance RNA templates. Its engineered thermal stability and reduced RNase H activity enable higher-fidelity, longer cDNA products for precise qPCR and transcriptomics.
-
Ganetespib (STA-9090): Innovating Hsp90 Inhibition in Cell D
2026-06-28
Explore how Ganetespib (STA-9090) is revolutionizing cancer research by targeting Hsp90 and modulating cell death pathways. This article offers a deep, cross-disciplinary analysis connecting advanced cytotoxicity models with new insights from viral cell death regulation.
-
Calpain Inhibitor I, ALLN: Technical Guidance for Research W
2026-06-27
Calpain Inhibitor I, ALLN is a potent, selective inhibitor for calpains and cathepsins, suitable for apoptosis assays, inflammation, and ischemia-reperfusion injury models. It should not be used for diagnostic or medical applications, and strict adherence to solubility and storage protocols is essential for reproducible research results.
-
IR-820 (New Indocyanine Green): Mechanistic Insights for Pre
2026-06-26
Explore the advanced mechanism and application strategies of IR-820 (New Indocyanine Green) for in vivo imaging. This article offers a unique, in-depth analysis of how IR-820 enables precise diseased tissue quantification and the design of next-generation experimental protocols.
-
Olsalazine Sodium: Molecular Insights for Xenobiotic & Tumor
2026-06-26
Explore the molecular mechanisms and assay strategies of Olsalazine Sodium, a potent mesalamine dimer, in xenobiotic transport and colorectal cancer research. This article provides novel insights beyond standard workflows, connecting transporter biology and anti-inflammatory prodrug design.
-
Innovations in In Vitro Evaluation of PARP Inhibitors in Can
2026-06-25
Schwartz’s doctoral dissertation advances the evaluation of anti-cancer drugs by distinguishing between proliferative arrest and cell death in in vitro systems. This approach provides more precise insight into drug responses, informing the development and assessment of novel PARP inhibitors like AZD2461 for breast cancer and DNA repair studies.
-
TP53 and DNA Damage Pathways Shape Calicheamicin ADC Respons
2026-06-25
This study used genome-wide CRISPR/Cas9 screening to identify TP53, ATM, and MDM2 as major modulators of acute leukemia cell sensitivity to calicheamicin-based antibody–drug conjugates (ADCs). The findings clarify mechanisms of resistance and highlight rational targets for improving ADC efficacy in acute leukemia.
-
Unveiling SOD Activity: Advanced Insights for Precision Assa
2026-06-24
Explore the scientific depth of Superoxide Dismutase Activity Assay Kits and their pivotal role in oxidative stress research. This article offers advanced analysis, practical considerations, and protocol guidance for maximizing SOD assay reliability.
-
Rucaparib (AG-014699): Applied Workflows for DNA Repair Rese
2026-06-23
Rucaparib (AG-014699) from APExBIO enables precise interrogation of DNA repair and radiosensitization in cancer models, with unique utility in both prostate cancer and hepatocellular carcinoma workflows. This article delivers actionable protocols, troubleshooting guidance, and the latest innovations in spliceosome-driven PARP inhibitor sensitivity.
-
5-(N,N-dimethyl)-Amiloride Hydrochloride: Advanced Ion Trans
2026-06-23
Explore the advanced applications of 5-(N,N-dimethyl)-Amiloride hydrochloride in dissecting ion transport and endothelial injury, with new insights on biomarker-guided assay design. Learn how this APExBIO reagent advances research beyond conventional NHE inhibition.
-
GST-Mediated Lambda-Cyhalothrin Resistance in M. usitatus
2026-06-22
This study uncovers how glutathione S-transferase (GST) upregulation in Megalurothrips usitatus enhances antioxidant defenses, driving resistance to the insecticide lambda-cyhalothrin. Functional GST inhibition using diethyl maleate significantly sensitizes the insects, offering a molecular basis for resistance management and improved pest control strategies.